Navigation Links
Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
Date:7/16/2009

COSTA MESA, Calif., July 16 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bullletin Board: OXBO) today announced that the company has closed on the first $5 million financing tranche with the Vatea Fund, Segregated Portfolio under a June 8, 2009 securities purchase agreement.

For additional details on the agreement, please see the Form 8-K filed with the SEC on June 8, 2009, which is available on the SEC website at www.sec.gov and through the investor relations page of the company website at www.oxybiomed.com.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes and cosmetic applications. More information is available at www.oxybiomed.com.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Brain Monitor Eliminates Need for Routine Oxygen With Propofol - Friedberg's Triad Unveiled
2. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
3. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
4. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
5. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
6. Oxygen Biotherapeutics, Inc. Expands Board of Directors
7. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
8. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
9. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
10. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
11. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Custom Learning Designs, Inc.(CLD) ... solution using Tin Can API combined with its ... is a leading developer of training content and ... worldwide. , Tin Can API is a ... and trainers more accurately measure the Return on ...
(Date:5/21/2013)... ISTANBUL , May 21, 2013 ...  European Dialysis and Transplant Association) is the biggest congress ... renal replacement therapy. Nearly 10,000 participants are in ... discuss the latest research findings. New pioneering studies have ... al. "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ...
(Date:5/21/2013)... New York , May 21, 2013 ... by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products ... Research, IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, ... 2.4 billion in 2011 and is expected to grow ... to reach an estimated value of USD 4.7 billion ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... new facility, based in Los Angeles, California is anticipated ... ability to supply its new, generation of ... ANGELES, Oct. 6 Today, Grifols SA (Grifols), a,global ... a new,92,000 square foot, intravenous immune globulin (IVIG) production ...
... ANTWERP and AALST , Belgium, AHMEDABAD, India ... Research, genae associates,Cardiovascular Center Aalst and J.B. ... a Core Laboratories joint venture, called imaeon., ... performance of medical images,analysis for clinical research ...
... deCODE genetics,(Nasdaq: DCGN ) today announced that ... Nasdaq Stock Market stating that for 10 consecutive trading,days ... below $50 million,the minimum level required for continued listing ... Marketplace Rule 4450(b)(1)(A). The notice,further stated that deCODE also ...
Cached Biology Technology:Grifols Breaks Ground on New IVIG Facility 2Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm 2deCODE Receives Nasdaq Deficiency Notice Relating to Market Value 2deCODE Receives Nasdaq Deficiency Notice Relating to Market Value 3
(Date:5/21/2013)... When infections occur in the body, stem cells ... multiplying and differentiating into mature immune cells that ... inflammation can deplete these cell populations, potentially leading ... as cancer. Now, a team of researchers led ... (Caltech) has found that, in mouse models, the ...
(Date:5/21/2013)... phosphatidylserine is a natural food supplement produced from ... and slow memory loss, it,s a popular treatment ... team headed by Prof. Gil Ast and Dr. ... Human Molecular Genetics have discovered that ... involved in degenerative brain disorders, including Parkinson,s disease ...
(Date:5/21/2013)... , Where? Copenhagen, Denmark: Bella Center Congress ... , Why? An annual meeting ... developments, manufacturing and installation, drawing on leading experiences from ... edition from a record of more than 900 abstracts ... plenary and oral presentations, more than 460 visual presentation, ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Common food supplement fights degenerative brain disorders 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4
... people in the United States alone suffer from rheumatoid arthritis ... in the joints. Now researchers at Brigham and Women,s Hospital ... for treating these diseases and others. Among its advantages, ... an affected joint, and could dispense that medicine on demand ...
... copepods rule the world, at least when it comes ... organisms in the seas, copepods are an important link ... To understand and predict how copepods respond to environmental ... new copepods are born, but how many are dying, ...
... Lockheed Martin (NYSE: LMT ) has been ... of the Year" by Frost and Sullivan, recognizing the ... high levels of customer value. "Lockheed ... that play an important role our customer,s law enforcement ...
Cached Biology News:Injectable gel could spell relief for arthritis sufferers 2Injectable gel could spell relief for arthritis sufferers 3Death -- not just life -- important link in marine ecosystems 2Lockheed Martin Named Biometrics "Company of the Year" by Frost and Sullivan 2
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
TGF-beta 2 MAb (Clone 8607)...
Fluorescein-CSCSSLMDKECVYFCHLDIIW (Disulfide bridge: 1-15 and 3-11)...
... for isolation and affinity purification of ... peptides. Hydrophobic, monodisperse magnetic particles (2.8 ... groups, further surface activation is not ... with optimal orientation for affinity purification ...
Biology Products: